BEIJING, Aug. 17 /PRNewswire-FirstCall/ -- China Biopharmaceuticals Holdings, Inc. , a leading Chinese pharmaceutical company focused on the development, manufacturing and distribution of innovative drugs in China, today announced that it has completed all required clinical trials for one of its new drugs, Nafamostate Mesilate and is waiting for final manufacturing and marketing approval from the State Food and Drug Administration of China (SFDA). The trials were conducted in ten hospitals throughout China.
The trial results will be sent to the SFDA for market and manufacturing approval, which is expected to be granted by the middle of 2007. Nafamostate Mesilate is a kallikrein inhibitor whose clinical indications include the treatment of Disseminated Intravascular Coagulation (DIC) and Acute Pancreatitis, as well as usage as an anticoagulant in heart operations. Currently, there are 1.4 million people suffering with DIC in China and CHBP is the only company approved for clinical trials of this drug in China. If granted production approval, in accordance with Chinese SFDA current policies, CHBP will have at least a 4 year manufacturing exclusive for this drug in China.
Mr. An Lufan, CHBP President and COO, stated, “Having successfully completed all required Nafamostate Mesilate clinical trials is a key step towards final approval and the subsequent manufacturing and marketing of this drug. This is only one of many new drug initiatives of our company. The successful completion of the required clinical trials demonstrates CHBP’s leading R&D capabilities, robust product pipeline and CHBP’s R&D team’s ability to successfully navigate the drug testing and approval process. If approved by the SFDA, our drug will help hundreds of thousands of patients in China.”
About China Biopharmaceuticals Holdings
China Biopharmaceutical Holdings, Inc (CHBP) is a research driven pharmaceutical company dedicated to the discovery, development, manufacturing and marketing of small and large molecule pharmaceutical products, including medicines, vaccines, and active pharmaceutical ingredients for various categories of diseases.
CHBP is a US public company with operating subsidiaries and senior management based in China.
For further information, please visit our website at www.cbioinc.com.
Safe Harbor Statement
The statements contained herein that are not historical facts are “forward looking statements” within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” or “anticipates” or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. In particular, our statements regarding the potential growth of the markets are examples of such forward- looking statements. The forward-looking statements include risks and uncertainties, including but not limited to, general economic conditions and regulatory developments, not within our control. The factors discussed herein and expressed from time to time in our filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed or implied by such statements. The forward looking statements are made only as of the date of this filing, and we undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
CONTACT: Chris Peng Mao, CEO 86-10-8525-1616 info@cbioinc.com Brian Rafferty 212-889-4350 brian.rafferty@taylor-rafferty.com
China Biopharmaceuticals Holdings, Inc.
CONTACT: Chris Peng Mao, CEO, +86-10-8525-1616, info@cbioinc.com; or BrianRafferty, +1-212-889-4350, brian.rafferty@taylor-rafferty.com
Web site: http://www.cbioinc.com/
